Fig. 2
Comparison of characteristics of single or combined tests compared to imipenem non-susceptible clinical category (x, imipenem 24) by using likelihood ratio graphs: ● Ticarcillin/clavulanate 24; ○ Ticarcillin/clavulanate 15; ▲ Piperacillin/tazobactam 21; ∆ Piperacillin/tazobactam 16; ■ Meropenem 22; ▣ Meropenem 25; 
Meropenem 27; ❏ Doripenem; ◈ Temocillin 8; ♦ Temocillin 12; ◊ Temocillin 15; ◣ Cefepime 24; ◥ Cefepime 26; ▼ Temocillin 12 & Piperacillin/tazobactam 16 [14]; 
Temocillin 15 & Ticarcillin/clavulanate 15; ⨁ Temocillin 15 & Ticarcillin/clavulanate 15 & Imipenem 22/Temocillin 15 & Ticarcillin/clavulanate 15 & Meropenem 22; ⨂ Temocillin 15 & Ticarcillin/clavulanate 15 & Imipenem 22 and Cefepime 26 for AmpC producers/Temocillin 15 & Ticarcillin/clavulanate 15 & Meropenem 22 and Cefepime 26 for AmpC producers; 
Temocillin 11 & Rosco KPC-MBL confirm kit [15]; ❖ Temocillin 8 & Rosco KPC-MBL confirm kit [13]; ★□ Temocillin 15 & Ticarcillin/clavulanate 15 & Meropenem 22 & Meropenem 32 on Mueller-Hinton-cloxacillin for AmpC producers; ✶ Temocillin 15 & Ticarcillin/clavulanate 15 & Meropenem 22 and Cefepime 26 & Meropenem 32 on Mueller-Hinton-cloxacillin for AmpC producers